Are these 7 ADC handling considerations on your radar?

Every new generation of ADC is more potent, more complex, and more valuable than the last. At the same time, manufacturing timelines are tightening, and safety expectations are rising. In this environment, traditional approaches to fluid handling and cold chain management quickly reach their limits. 

The following 7 considerations increasingly define how ADC handling is approached in real manufacturing environments, to achieve the safety, precision, and scalability that have become inseparable requirements.

1. Operator safety must come first

Antibody-drug conjugates (ADCs) introduce cytotoxic risk directly into routine liquid handling operations in manufacturing facilities. Even minimal exposure may be hazardous for operators, particularly during open or semi‑open process steps such as manual filling, draining, or transfer operations.

For this reason, closed handling concepts have become essential rather than optional. EU GMP Annex 1 explicitly promotes the use of closed systems to reduce both product contamination and operator exposure. In practical terms, this includes fully sealed fluid paths, minimized manual intervention, and automation wherever feasible.

In cold chain handling, container closure integrity is of highest importance. Freezing and subsequent cold‑chain handling can impose mechanical stress on single‑use bioprocess containers, potentially resulting in leakage or breakage. Secondary packaging solutions, such as the RoSS® shell, provide an additional protective barrier, reducing the risk of product loss while serving as a critical layer of protection for both product quality and personnel safety.

2. Light as invisible threat for ADCs

ADCs are especially susceptible because their components – the antibody, linker, and payload – exhibit different photostability profiles, making gradual degradation possible even in the absence of immediately visible changes.[[1]]. Although UV light represents only a small portion of the overall light spectrum, it is the most energetic component and therefore the most critical for light‑sensitive biologics. However, light exposure is unavoidable in manufacturing environments, for example as USP <790> requires visual inspection under defined lighting conditions to assess product quality.[[2]] Unnecessary light exposure can, however, be minimized elsewhere in the process though. 

So how can manufacturers protect ADCs from light? Only a limited number of single-use bags provide inherent UV protection through the film material. Yet again the RoSS® shell as secondary packaging for 2D bags can play an important role as it is designed not only to protect against mechanical damage of the bag, but also fully encloses single‑use bags and assemblies tamper-evidently and minimize ambient light exposure during handling and transport. Where required, UV‑protective single‑use bags with a black film can provide an additional layer of protection against light exposure, helping preserve product quality beyond the mandatory inspection steps.

Blocking UV light from biopharmaceuticals

[[download-1-email-detailed]]

3. Patient safety already starts in the fluid path

Patient safety in ADC manufacturing is not (only) determined at the bedside – it is engineered already into the fluid path through manufacturing processes. Closed system devices play a decisive role in determining how accurately, consistently, and safely a drug product is transferred and filled. Variations in fluid‑path geometry or internal volumes across closed system transfer devices can lead to meaningful differences in holdup volume, product (quality) loss, and drug‑product interaction. Such incompatibility may result in compromising product quality and dose accuracy.[[1]]

High‑precision, recipe‑driven fluid management systems such as RoSS.FILL are designed to address these risks by controlling fluid‑path design, minimizing residual volumes, and ensuring material compatibility across the complete assembly. Reproducible filling performance and defined drainage behavior reduce dose‑to‑dose variability and help ensure that the target fill volume is delivered consistently. By focusing on controlled, yet modular closed system fluid paths early in development, manufacturers establish a robust foundation for drug‑product integrity, process robustness, and, ultimately, patient safety. HPAPI fluid management entails further process steps and equipment to provide restricted barrier systems and safe fluid transfers.

Getting HPAPI fluid management to controlled efficiency

4. What is the weakest link(er) when freezing?

Freezing and thawing are among the most stressful moments in the life of an ADC. Cryoconcentration, local pH shifts, aggregation, and denaturation are well‑documented risks for biologics. Furthermore, the linker often represents the weakest structural element in ADCs. Temperature‑ and pH‑sensitive linkers can be altered by uncontrolled freeze‑thaw stress, reducing conjugation integrity and stability.

Controlled, recipe‑driven freezing of antibody-drug conjugates in single-use bags and bottles replaces uncertainty with reproducibility. Managing cooling rates, phase transitions, and thawing profiles helps preserve critical quality attributes (CQA) throughout cold storage and transport.

5. ADC value keeps rising

Modern ADCs are steadily increasing in value per milliliter. Higher drug‑to‑antibody ratios, more potent cytotoxic payloads, and advanced linker technologies are significantly raising the stakes[[3]].

At the same time, the industry is already moving beyond classical ADCs toward next‑generation bioconjugate formats. For example, novel bioconjugates may combine vaccines with different polysaccharides, while nanoparticles can be conjugated with small molecules to enable highly targeted therapeutic delivery.[[4]]

In this environment, product loss due to contamination, hold‑up volume, single-use bag breakages or inaccurate filling is no longer acceptable. Precision in ADC handling is therefore not only a matter of operational efficiency – it is essential to protecting therapeutic value.

6. ADC manufacturing never stands still

ADC programs rarely follow a linear path. Batch volumes fluctuate, clinical indications evolve, and production is often distributed across multiple sites or partners or fully outsourced to CDMOs.

Given the volatile market dynamics of ADC manufacturing, it is challenging for manufacturers to maintain consistently aligned process flexibility. This variability places significant pressure on manufacturers during tech transfer, requiring them to:

• Scale batch volumes without process redesign
• Increase throughput within tight timelines
• Transfer processes seamlessly to CDMOs
• Adapt container formats quickly

Conventional, rigid systems are poorly suited to these demands. In contrast, modular and scalable platforms enable manufacturers to respond to changing requirements without compromising safety, process control, or compliance. Additionally, the straightforward implementation and adjustment of automated filling systems for scale-up or scale-out significantly improves operational efficiency and reproducibility.

[[download-2-email-detailed]]

7. End‑to‑end process thinking wins

Many ADC challenges cannot be solved in isolation. Operator safety, product quality, cold chain stability, and scalability are interdependent: End‑to‑end approaches combine closed, automated fluid handling, protective secondary packaging, controlled freezing, storage, and thawing.

Modular systems that scale with demand are not only easier to integrate in existing processes, but also seamlessly scalable. In addition, reducing interfaces and manual steps improves robustness and makes complex ADC processes easier to control over time.

[[download-3-email-detailed]]

Mastering ADC handling with Single Use Support

Single Use Support supports manufacturers with end‑to‑end solutions for safe, closed, and scalable ADC fluid and cold chain management. From automated filling and protected storage to controlled freezing and thawing, the technologies are designed to reduce risk while preserving product integrity. This integrated approach helps manufacturers handle increasingly potent and valuable ADCs with confidence across development and commercial manufacturing.

ADC Handling with Single Use Support

References

1. Patnaik, P.: ADC Manufacturing’s biggest CMC challenges and ways to approach them, in: ADCs: ADC Manufacturing's Biggest CMC Challenges And Ways To Approach Them
2. USP-NF/PF: 〈790〉 Visible Particulates in Injections
3. Tao J, et al.: Dual-payload antibody-drug conjugates: Taking a dual shot:  ScienceDirect
4. Kwon, Y.:  A Love for Complexity: ADC Drug Development